Value through Innovation24 April 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim LUX-Breast 1 and LUX-Breast 3 data at San Antonio Breast Cancer Symposium (SABCS)

- For Media Outside the UK, US and Canada Only

New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers

- For Non-US/Non-UK/Non-Canadian Media

Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach


Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

- For media outside UK, US and Canada only

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

- For media outside UK, US and Canada

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

- For Non-US/Non-UK/Non-Canadian Media

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim "Runs" to support vital programs in Diabetes and Stroke


New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy

- For Media In Asian Countries Only For Whom The Data Is Relevant For media outside the US, the UK & Canada only

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva® Respimat® in asthma

- For media outside the US, the UK & Canada only

FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice

- Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries


Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments

- For Ex-US and Ex-UK Media Only

Winners of the 2014 European PRRS Research Award announced


Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis


- For media outside UK, US and Canada

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund


Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

- For Ex-US and Ex-UK Media Only